CellBion Co., Ltd. (KOSDAQ:308430)
South Korea · Delayed Price · Currency is KRW 30,500
-1,100 (-3.48%)
At close: Apr 9, 2026
CellBion Revenue
In the year 2025, CellBion had annual revenue of 1.95B KRW, down -15.05%. CellBion had revenue of 381.91M in the quarter ending December 31, 2025, a decrease of -32.61%.
Revenue
1.95B
Revenue Growth
-15.05%
P/S Ratio
198.90
Revenue / Employee
n/a
Employees
n/a
Market Cap
386.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.95B | -344.73M | -15.05% |
| Dec 31, 2024 | 2.29B | 818.55M | 55.64% |
| Dec 31, 2023 | 1.47B | -291.63M | -16.54% |
| Dec 31, 2022 | 1.76B | 846.00M | 92.27% |
| Dec 31, 2021 | 916.88M | -443.71M | -32.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NOVAREX | 404.26B |
| Myung In Pharmaceutical LTD. | 287.25B |
| GREEN CROSS WellBeing | 164.68B |
| DAE HWA Pharmaceutical | 143.06B |
| OPTUS Pharmaceutical | 87.16B |
| High Tech Pharm | 70.18B |
| Vivozon Pharmaceutical | 59.34B |
| HEM Pharma | 12.98B |